The Syn-D Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein and blood P-Tau 217 in Patients with Mild Cognitive Impairment
Objective: To quantify the deposition of cutaneous P-SYN and blood P-Tau 217 in patients with suspected DLB and AD at the mild cognitive impairment (MCI)…Plasma Biomarkers Predict Clinical Outcomes in Individuals with Neuronal α-Synuclein Disease and Amyloid-β Co-Pathology
Objective: We examined whether the plasma biomarkers pTau181, pTau217, GFAP, NfL, and Aβ42/40 are associated with cognitive, functional, and motor outcomes in individuals with neuronal…A Longitudinal Quantitative Assessment of Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies
Objective: To report the quantitative change in cutaneous phosphorylated alpha-synuclein (P-SYN) deposition over time in patients with dementia with Lewy bodies (DLB) in a longitudinal…Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)
Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…Patterns and Predictors of Cholinesterase Inhibitor Use in Dementia with Lewy Bodies
Objective: The objective of this study was to identify the patterns and predictors of cholinesterase inhibitor (ChEI) prescribing in Dementia with Lewy bodies (DLB) patients.…Stratification study of alpha-synucleinopathy by body fluid biomarkers
Objective: This study aims to stratify patients with Parkinson's disease (PD) based on clinical features and several disease-associated biomarkers by analyzing the relationship between biomarkers,…Development of the Lewy Body Dementia Domain Rating Scale (LBD-DRS): A disease-specific outcome measure
Objective: To develop and refine the Lewy Body Dementia Domain Rating Scale (LBD-DRS) as a disease-specific outcome measure tailored to the unique clinical features of…Neural Signatures of Hallucination Emergence in Dementia with Lewy Bodies
Objective: REM sleep behavior disorder (RBD) is a prodromal state for alpha-synucleinopathy. Here, we present a behavioral marker for hallucination propensity that distinguishes Dementia with…Advancing LBD Diagnosis: EEG Biomarkers for Cognitive Fluctuations
Objective: The objective of the study was to identify EEG features associated with cognitive fluctuations in patients with Lewy body dementia (LBD). Background: Cognitive fluctuations…Immune cell changes in early Dementia with Lewy Bodies
Objective: To examine if immune cell changes are present in early stages of Dementia with Lewy Bodies (DLB). Background: Evidence for inflammation in synucleinopathies has…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 23
- Next Page »